{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T16:09:11Z","timestamp":1726848551728},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Italian Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003197","name":"AIFA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.phrs.2014.10.006","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T01:16:25Z","timestamp":1414631785000},"page":"31-39","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: Systematic review and meta-analysis"],"prefix":"10.1016","volume":"92","author":[{"given":"Paolo","family":"Pellegrino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Radice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2014.10.006_bib0005","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1086\/648963","article-title":"Epidemiological profile of meningococcal disease in the United States","volume":"50","author":"Harrison","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2014.10.006_bib0010","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2014.10.006_bib0015","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.vaccine.2011.11.051","article-title":"A tetravalent meningococcal serogroups a, c, w-135, and y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with twinrix((r)) in subjects aged 11\u201317 years: an open, randomised, controlled trial","volume":"30","author":"Ostergaard","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2014.10.006_bib0020","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s10096-014-2102-2","article-title":"Epidemiological analysis on two decades of hospitalisations for meningitis in the United States","volume":"33","author":"Pellegrino","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.phrs.2014.10.006_bib0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/adc.2008.152090","article-title":"Guideline review: management of invasive meningococcal disease, sign","volume":"94","author":"Baumer","year":"2009","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"10.1016\/j.phrs.2014.10.006_bib0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","article-title":"Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.phrs.2014.10.006_bib0035","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.10.006_bib0040","first-page":"85","article-title":"Meningococcal serogroups a, c, w-135, and y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease","volume":"7","author":"Hedari","year":"2014","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.phrs.2014.10.006_bib0045","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2014.10.006_bib0050","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection \u2013 serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2014.10.006_bib0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/INF.0b013e3182784143","volume":"32","author":"Ruiz-Palacios","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.phrs.2014.10.006_bib0060","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.ijid.2012.10.001","article-title":"Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups a, c, w-135, and y tetanus toxoid conjugate vaccine (menacwy-tt)","volume":"17","author":"Ostergaard","year":"2013","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.phrs.2014.10.006_bib0065","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1128\/CVI.00162-13","article-title":"Meningococcal polysaccharide a o-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase iii study of healthy adults aged 18 to 25 years","volume":"20","author":"Lupisan","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.phrs.2014.10.006_bib0070","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00431-012-1924-0","article-title":"Immunogenicity and safety of the quadrivalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine (menacwy-tt) in 2\u201310-year-old children: results of an open, randomised, controlled study","volume":"172","author":"Knuf","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.phrs.2014.10.006_bib0075","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0b013e31828693c5","article-title":"One or two doses of quadrivalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children","volume":"32","author":"Klein","year":"2013","journal-title":"Pediatr Infect Dis"},{"key":"10.1016\/j.phrs.2014.10.006_bib0080","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40266-013-0065-0","article-title":"Immunogenicity and safety of a quadrivalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine (menacwy-tt) administered to adults aged 56 years and older: results of an open-label, randomized, controlled trial","volume":"30","author":"Dbaibo","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.phrs.2014.10.006_bib0085","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2334-13-116","article-title":"Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups a, c, w-135, and y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study","volume":"13","author":"Borja-Tabora","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.phrs.2014.10.006_bib0090","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.22166","article-title":"Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine in toddlers","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.phrs.2014.10.006_bib0095","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.4161\/hv.22165","article-title":"A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine in children aged 2\u201310 years","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.phrs.2014.10.006_bib0100","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4161\/hv.20229","article-title":"Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (menacwy-tt) in toddlers and young children","volume":"8","author":"Knuf","year":"2012","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.phrs.2014.10.006_bib0105","doi-asserted-by":"crossref","first-page":"e608","DOI":"10.1016\/j.ijid.2012.04.006","article-title":"The tetravalent meningococcal serogroups a, c, w-135, and y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine","volume":"16","author":"Dbaibo","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.phrs.2014.10.006_bib0110","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4161\/hv.20211","article-title":"The immunogenicity and safety of an investigational meningococcal serogroups a, c, w-135, y tetanus toxoid conjugate vaccine (acwy-tt) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study","volume":"8","author":"Dbaibo","year":"2012","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.phrs.2014.10.006_bib0115","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.20212","article-title":"The investigational meningococcal serogroups a, c, w-135, y tetanus toxoid conjugate vaccine (acwy-tt) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults","volume":"8","author":"Aplasca-De Los Reyes","year":"2012","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.phrs.2014.10.006_bib0120","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal acwy tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.phrs.2014.10.006_bib0125","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups a, c, w-135, y tetanus toxoid conjugate (menacwy-tt) vaccine administered in the second year of life and in young children","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2014.10.006_bib0130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal a, c, w-135 and y-tetanus toxoid candidate conjugate (menacwy-tt) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2014.10.006_bib0135","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups a, c, w-135 and y conjugate vaccine is well tolerated and immunogenic when co-administered with measles\u2013mumps\u2013rubella\u2013varicella vaccine during the second year of life: an open, randomized controlled trial","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2014.10.006_bib0140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/hv.7.2.14068","article-title":"Safety and immunogenicity of a tetravalent meningococcal serogroups a, c, w-135 and y conjugate vaccine in adolescents and adults","volume":"7","author":"Bermal","year":"2011","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.phrs.2014.10.006_bib0145","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups a, c, w-135, and y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-acwy polysaccharide vaccine with an acceptable safety profile","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.phrs.2014.10.006_bib0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jpids\/pit058","article-title":"Comparison of the safety and immunogenicity of a novel quadrivalent meningococcal acwy-tetanus toxoid conjugate vaccine and a marketed quadrivalent meningococcal acwy-diphtheria toxoid conjugate vaccine in healthy individuals 10\u201325 years of age","volume":"3","author":"Halperin","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.phrs.2014.10.006_bib0155","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1086\/515346","article-title":"Induction of immunologic refractoriness in adults by meningococcal c polysaccharide vaccination","volume":"178","author":"Granoff","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.phrs.2014.10.006_bib0160","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00099-14","article-title":"The immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines: a randomised clinical trial in UK adults","author":"Ramasamy","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.phrs.2014.10.006_bib0165","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.phrs.2014.10.006_bib0170","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","article-title":"Meningococcal quadrivalent (serogroups a, c, w135 and y) tetanus toxoid conjugate vaccine (nimenrix)","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2014.10.006_bib0175","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1586\/erv.12.32","article-title":"Menacwy-tt vaccine for active immunization against invasive meningococcal disease","volume":"11","author":"Papaevangelou","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.phrs.2014.10.006_bib0180","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1517\/14712598.2013.812629","article-title":"Quadrivalent meningococcal serogroups a, c, w, and y tetanus toxoid conjugate vaccine (menacwy-tt): a review","volume":"13","author":"Ghanem","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.phrs.2014.10.006_bib0185","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.autrev.2014.01.054","article-title":"On the relationship between human papilloma virus vaccine and autoimmune diseases","volume":"13","author":"Pellegrino","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.phrs.2014.10.006_bib0190","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10654-013-9830-y","article-title":"No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus","volume":"28","author":"Pellegrino","year":"2013","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.phrs.2014.10.006_bib0195","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1177\/1352458513502114","article-title":"Can hpv immunisation cause adem? Two case reports and literature review","volume":"20","author":"Pellegrino","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.phrs.2014.10.006_bib0200","doi-asserted-by":"crossref","first-page":"pe77766","DOI":"10.1371\/journal.pone.0077766","article-title":"Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems","volume":"8","author":"Pellegrino","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2014.10.006_bib0205","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/aji.12190","article-title":"On the association between human papillomavirus vaccine and primary ovarian failure","volume":"71","author":"Pellegrino","year":"2014","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.phrs.2014.10.006_bib0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/EDE.0000000000000033","article-title":"Human papillomavirus vaccine in patients with systemic lupus erythematosus","volume":"25","author":"Pellegrino","year":"2014","journal-title":"Epidemiology"},{"key":"10.1016\/j.phrs.2014.10.006_bib0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.phrs.2014.09.003","article-title":"Can vaccines interact with drug metabolism?","volume":"92","author":"Pellegrino","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2014.10.006_bib0220","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.phrs.2014.08.002","article-title":"Predicting post-vaccination autoimmunity: who might be at risk?","volume":"92","author":"Soriano","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2014.10.006_bib0225","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1016\/j.vaccine.2014.06.068","article-title":"Efficacy of vaccination against influenza in patients with multiple sclerosis: the role of concomitant therapies","volume":"32","author":"Pellegrino","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2014.10.006_bib0230","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coi.2014.03.008","article-title":"Immunosenescence influenza vaccination and the elderly","volume":"29C","author":"Haq","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.phrs.2014.10.006_bib0235","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.vaccine.2014.01.090","article-title":"Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts","volume":"32","author":"Haralambieva","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2014.10.006_bib0240","doi-asserted-by":"crossref","first-page":"pe1002344","DOI":"10.1371\/journal.ppat.1002344","article-title":"Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery?","volume":"7","author":"Poland","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.phrs.2014.10.006_bib0245","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/aje\/kwu193","article-title":"Re postelimination transmission of measles in the US","volume":"180","author":"Pellegrino","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.phrs.2014.10.006_bib0250","doi-asserted-by":"crossref","DOI":"10.1038\/tpj.2014.57","article-title":"The first steps towards the era of personalised vaccinology: predicting adverse reactions","author":"Pellegrino","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.phrs.2014.10.006_bib0255","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.phrs.2014.03.001","article-title":"Statins from cholesterol-lowering drugs to novel immunomodulators for the treatment of th17-mediated autoimmune diseases","volume":"88","author":"Ulivieri","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2014.10.006_bib0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.phrs.2014.04.010","article-title":"Statins role in the prevention and treatment of sepsis","volume":"88","author":"Dobesh","year":"2014","journal-title":"Pharmacol Res"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814001674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814001674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:22:11Z","timestamp":1538094131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661814001674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":52,"alternative-id":["S1043661814001674"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2014.10.006","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: Systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2014.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}